Actively Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-03-27
31
Participants Needed
1
Research Sites
166 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
G
Genmab
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
CONDITIONS
Official Title
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Ability and willingness to provide informed consent or have a legally authorized representative provide it
- Ability to comply with study protocol as judged by the investigator
- ECOG performance status of 0 to 2
- Pathology report confirming eligible lymphoma diagnosis
- Documented CD20 positive tumor cells on most recent biopsy
- Failure to respond to frontline standard care therapy containing anthracycline and anti-CD20 antibody
- Eligibility and consent to receive a commercially available anti-CD19 CAR T cell therapy
- Presence of at least one measurable lesion by PET/CT, CT, or MRI scans
- Adequate laboratory results
- Resolution of prior therapy toxicities to a level safe for trial participation
- Ability and willingness to use effective contraception
You will not qualify if you...
- Inability or unwillingness to provide informed consent
- Prior solid organ transplant
- Primary CNS lymphoma or active secondary CNS lymphoma involvement
- History of autoimmune disease causing permanent immunosuppression or requiring chronic immunosuppressive therapy, except stable hypothyroidism, some lymphoma-related autoimmune conditions in remission, or certain well-controlled skin conditions
- Use of systemic immunosuppressive medications beyond specified exceptions
- Known past or current cancers other than those allowed and in remission
- Clinically significant cardiovascular disease
- Active infections including hepatitis B, hepatitis C, HIV, or other serious infections
- Clinically significant pulmonary disease requiring chronic oxygen or high-dose corticosteroids
- Uncontrolled seizure disorder
- Receipt of live vaccine within 4 weeks prior to consent
- Pregnancy or breastfeeding
- Any serious medical or laboratory abnormalities precluding safe participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
B
Brittany Koch
CONTACT
K
Kaitlin Kennard
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here